Kalshi has launched a pilot program allowing eligible users to trade event contracts tied to clinical-trial results and U.S. Food and Drug Administration decisions.
The contracts ask binary questions: Will a late-stage trial meet its registered primary endpoint? Will the FDA approve a named drug within a specified period? Kalshi calls the products “prediction markets” and “event contracts,” rather than bets. The structure is nevertheless similar to sports-betting markets: users buy Yes or No positions, and the successful side settles at $1 per contract.
Kalshi said the launch includes more than a dozen FDA-decision markets. Named examples include whether the FDA will approve Gilead and Arcellx’s multiple-myeloma therapy anito-cel, as well as a contract on whether AriBio’s AR1001 Alzheimer’s trial will meet its primary endpoint. AppliedXL, Kalshi’s partner in the program, will determine outcomes using criteria fixed before trading begins and public records such as ClinicalTrials.gov results and FDA approval letters.
The pilot is initially limited to late-stage trials, with contracts listed only after patient enrollment has closed. Kalshi will require employment verification and prohibit trading by anyone holding material nonpublic information. Filed rules specifically cover relevant pharmaceutical employees, FDA personnel, investigators, research organizations, laboratories, statisticians, consultants, advisers and certain family or household members.
KalshiEX has operated as a CFTC-designated contract market since 2020. The biotech contracts were filed through the federal exchange-certification process. That establishes regulatory oversight of the trading venue; it does not mean the CFTC or FDA has validated the contracts as medically accurate forecasting tools.
The launch raises immediate questions about ethics, legality, patient safety and market integrity. Among the issues are whether existing rules can prevent insider trading and manipulation, protect confidential clinical data, and stop market prices from being mistaken for scientific evidence or medical guidance. These concerns will be examined in a forthcoming analysis.
OncoDaily will conduct a fuller analysis and will examine liquidity, insider-trading enforcement, manipulation, medical ethics and the risk that patients or investors mistake market prices for scientific evidence.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada